Kettering Health has continued to monitor any studies that show benefit or risk in utilizing Ivermectin or any other treatment modality for COVID-19.
Currently, Ivermectin is not authorized by the Food and Drug Administration (FDA) for usage in the treatment of COVID-19. The National Institutes of Health (NIH), which has taken the lead in delineating the treatment of COVID-19, states there is insufficient data to support utilizing this drug in the treatment of COVID-19. Recently, data from poison control centers indicate a large increase in calls regarding toxicity for high dosing of Ivermectin.
Ivermectin is on the Kettering Health formulary, and a small amount is kept for physicians to treat patients with parasitic infections. Accepted clinical guidelines do not support the use of Ivermectin for COVID-19 treatment or prevention. Thus, any prescriptions or orders for non-FDA-approved criteria will not be filled. Families or visitors of inpatients with COVID-19 may not provide an outside supply of this or any other medication not prescribed by their hospital physicians.
Any follow-up questions should be directed to the campus Chief Medical Officer (CMO) or Pharmacy leadership.